Empagliflozin vs Enavogliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Empagliflozin · Jardiance
Marketed by Boehringer Ingelheim and partners
NCT01131676 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial enrolling 7,064 participants. The hard clinical primary endpoint was met: pooled empagliflozin was non-inferior and also statistically superior to placebo for 3-point MACE, with 10.5% versus 12.1% of participants experiencing an event (HR 0.86; p=0.0382).
Next expected readout: November 2026 · NCT05057806 (registry estimate)
Reported efficacy
Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1% (met)
Result source: NCT01131676
Enavogliflozin · Envlo
Marketed by Daewoong Pharmaceutical and partners
NCT04634500 · Phase 3 · completed
This Phase 3 trial randomly assigned 200 people with type 2 diabetes to enavogliflozin or to dapagliflozin, with participants and investigators unaware of assignment. It was designed to show enavogliflozin was not worse than dapagliflozin at lowering HbA1c over 24 weeks, within a margin of 0.35 percentage points. It met that test: HbA1c fell by 0.80 percentage points on enavogliflozin against 0.75 on dapagliflozin, a difference of 0.04 points (95% CI -0.21 to 0.12).
Next expected readout: December 2026 · NCT06399835 (registry estimate)
Reported efficacy
Change from baseline in HbA1c (at 24 weeks): Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35% (met)
Result source: NCT04634500
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Empagliflozin | Enavogliflozin |
|---|---|---|
| HbA1c, change | -0.7% vs -0.2%−0.5 vs placeboNCT0115960032 other results
| -0.8% vs -0.8%avs dapagliflozinNCT04634500 |
| Body weight, change (kg) | -2.1 vs -0.4−1.7 vs placeboNCT0115960018 other results
| —Not posted · NCT05376969 |
| HbA1c below 7% | 34.6% vs 24.5%+10.1 vs placeboNCT034295433 other results
| —Not posted · NCT05376969 |
| Fasting plasma glucose, change | -1.8 vs 0.3−2.1 vs placeboNCT0173478511 other results
| —Not posted · NCT05376969 |
| 3-point MACE (% with event) | 10.4% vs 12.1%−1.7 vs placeboNCT011316762 other results
| —Not posted · NCT05376969 |
HbA1c, change
- Empagliflozin
- -0.7% vs -0.2%−0.5 vs placeboNCT01159600
32 other results
- -0.8% vs -0.2% NCT01159600
- -0.8% vs -0.2% NCT01159600
- -0.8% vs -0.2% NCT01159600
- -1.1% vs -0.1% NCT04233801
- -0.7% vs 0.1% NCT02182830
- -2.8% vs -0.2% NCT01159600
- -2.5% vs -0.2% NCT01159600
- -1.1% vs -0.1% NCT04233801
- -0.9% vs -0.3% NCT02489968
- -0.6% vs 0.1% NCT01734785
- -0.9% vs -0.3% NCT02489968
- -0.9% vs 0.2% NCT02453555
- -0.7% vs 0.1% NCT01734785
- -1.4% vs -1.8% NCT01719003
- -2.1% vs -1.8% NCT01719003
- -0.2% vs 0.3% NCT03429543
- -1.4% vs -1.8% NCT01719003
- -1.9% vs -1.8% NCT01719003
- -2.1% vs -1.8% NCT01719003
- -2.0% vs -1.8% NCT01719003
- -0.5% vs 0.3% NCT03429543
- 0.1% vs 0.3% NCT03429543
- -1.1% vs 0.1% NCT02453555
- -1.1% vs -0.0% NCT02453555
- -0.2% vs 0.1% NCT03429543
- -0.9% vs 0% NCT02589639
- -0.6% vs -0.2% NCT01649297
- -0.7% vs -0.2% NCT01649297
- -0.7% vs -0.1% NCT04531462
- -1% vs 0% NCT02589639
- -0.8% vs -0.2% NCT01649297
- -0.7% vs -0.2% NCT01649297
- Enavogliflozin
- -0.8% vs -0.8%avs dapagliflozinNCT04634500
Body weight, change (kg)
- Empagliflozin
- -2.1 vs -0.4−1.7 vs placeboNCT01159600
18 other results
- -2.2 vs -0.4 NCT01159600
- -2.5 vs -0.4 NCT01159600
- -2.4 vs -0.4 NCT01159600
- -0.8 vs -0.0 NCT03429543
- -2.0 vs 0.0 NCT04233801
- -2.2 vs -1.0 NCT02182830
- -1.3 vs -0.4 NCT01159600
- -1.3 vs -0.4 NCT01159600
- -1.3 vs 0.0 NCT04233801
- -2.5 vs -0.3 NCT01734785
- -3.1 vs -0.3 NCT01734785
- 1.3 vs -0.0 NCT03429543
- -2.4 vs -1.3 NCT01719003
- -2.4 vs -1.3 NCT01719003
- -3.8 vs -1.3 NCT01719003
- -3.0 vs -1.3 NCT01719003
- -3.5 vs -1.3 NCT01719003
- -2.8 vs -1.3 NCT01719003
- Enavogliflozin
- —Not posted · NCT05376969
HbA1c below 7%
- Empagliflozin
- 34.6% vs 24.5%+10.1 vs placeboNCT03429543
3 other results
- 16.7% vs 8.2% NCT04233801
- 30.1% vs 8.2% NCT04233801
- 66.7% vs 24.5% NCT03429543
- Enavogliflozin
- —Not posted · NCT05376969
Fasting plasma glucose, change
- Empagliflozin
- -1.8 vs 0.3−2.1 vs placeboNCT01734785
11 other results
- -1.5 vs 0.3 NCT01734785
- -1.8 vs -1.8 NCT01719003
- -1.6 vs -1.8 NCT01719003
- -2.8 vs -1.8 NCT01719003
- -2.4 vs -1.8 NCT01719003
- -2.6 vs -1.8 NCT01719003
- -2.5 vs -1.8 NCT01719003
- -1.0 vs -0.0 NCT01649297
- -1.3 vs -0.0 NCT01649297
- -1.5 vs -0.0 NCT01649297
- -1.2 vs -0.0 NCT01649297
- Enavogliflozin
- —Not posted · NCT05376969
3-point MACE (% with event)
- Empagliflozin
- 10.4% vs 12.1%−1.7 vs placeboNCT01131676
2 other results
- 10.5% vs 12.1% NCT01131676
- 10.5% vs 12.1% NCT01131676
- Enavogliflozin
- —Not posted · NCT05376969
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Empagliflozin: 4 of 4 rows · Enavogliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Empagliflozin | Enavogliflozin |
|---|---|---|
| Dropout rate | 23.7%10 mga NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 40 more results23.2%25 mg NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 8%10mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.7%10mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 8.7%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.5%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 8.4%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 15.9%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 —10 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 —25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 6.2%10 mg NCT04531462 · Phase 4 · registry result, not featured evidence —10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 11.2%10 mg NCT02589639 · Phase 4 · registry result, not featured evidence 4.4%25 mg NCT02589639 · Phase 4 · registry result, not featured evidence 9.4%10 mg NCT02589626 · Phase 4 · registry result, not featured evidence 6.1%25 mg NCT02589626 · Phase 4 · registry result, not featured evidence —25mg NCT02589626 · Phase 4 · registry result, not featured evidence 2.7%10 mg NCT04233801 · Phase 3 · registry result, not featured evidence 5.5%25 mg NCT04233801 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 18.1%10 mg-25 mg NCT02182830 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 7%10 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 10.2%25 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 7.5%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 5.3%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 10%12.5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 9.9%5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 7.7%5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 0%10 mg NCT01947855 · Phase 3 · registry result, not featured evidence 0%25 mg NCT01947855 · Phase 3 · registry result, not featured evidence —Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 12.1%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —25 mg NCT02632747 · Phase 2 · registry result, not featured evidence 8.6%10 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 6%25 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 6.4%12.5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence 7.8%5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence | — |
| Discontinued due to AEs | 11.4%10 mga NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 40 more results11.6%25 mg NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 2.7%10mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.9%10mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 3.2%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.9%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.3%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 1.4%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 —10 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 —25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 4.6%10 mg NCT04531462 · Phase 4 · registry result, not featured evidence —10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 5.6%10 mg NCT02589639 · Phase 4 · registry result, not featured evidence 3.3%25 mg NCT02589639 · Phase 4 · registry result, not featured evidence 3.1%10 mg NCT02589626 · Phase 4 · registry result, not featured evidence 3%25 mg NCT02589626 · Phase 4 · registry result, not featured evidence —25mg NCT02589626 · Phase 4 · registry result, not featured evidence —10 mg NCT04233801 · Phase 3 · registry result, not featured evidence —25 mg NCT04233801 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg-25 mg NCT02182830 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 1.7%10 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 2.4%25 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 0%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 3.5%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 2.9%12.5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 2.3%5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination —10 mg NCT01947855 · Phase 3 · registry result, not featured evidence —25 mg NCT01947855 · Phase 3 · registry result, not featured evidence —Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 4.8%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —25 mg NCT02632747 · Phase 2 · registry result, not featured evidence 5.9%10 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 2.3%25 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 2.3%12.5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence 1.8%5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence | — |
| Serious AEs | 37.4%10 mga NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 40 more results39%25 mg NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 4.9%10mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.2%10mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 0.5%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 5%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.3%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 1.4%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 5.4%10 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 0%25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 —10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 12.3%10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 10.5%10 mg NCT02589639 · Phase 4 · registry result, not featured evidence 8.9%25 mg NCT02589639 · Phase 4 · registry result, not featured evidence 6.3%10 mg NCT02589626 · Phase 4 · registry result, not featured evidence —25 mg NCT02589626 · Phase 4 · registry result, not featured evidence 3%25mg NCT02589626 · Phase 4 · registry result, not featured evidence 13.7%10 mg NCT04233801 · Phase 3 · registry result, not featured evidence 9.6%25 mg NCT04233801 · Phase 3 · registry result, not featured evidence 5.2%25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 0.9%10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 3.7%10 mg-25 mg NCT02182830 · Phase 3 · registry result, not featured evidence 3.6%25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 4.5%10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 0.6%10 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 1.8%25 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 3.8%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.2%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 3.5%12.5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.2%5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 0%10 mg NCT01947855 · Phase 3 · registry result, not featured evidence 0%25 mg NCT01947855 · Phase 3 · registry result, not featured evidence 6.4%Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence 7.1%Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination —Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence 0%25 mg NCT02632747 · Phase 2 · registry result, not featured evidence 2.3%10 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 0.9%25 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 2.3%12.5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence 3.2%5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence | — |
| Most frequent reported AEs | 10 mga hypoglycaemia 29.6% (placebo 29.4%) urinary tract infection 14.5% (placebo 14.7%) hyperglycaemia 9.3% (placebo 18.1%) NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 37 more results25 mg hypoglycaemia 28.7% (placebo 29.4%) urinary tract infection 14.4% (placebo 14.7%) nasopharyngitis 9.4% (placebo 9.3%) NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 10mg hypoglycaemia 15.6% (placebo 9.8%) urinary tract infection 9.4% (placebo 6.7%) nasopharyngitis 8% (placebo 4.9%) NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 10mg nasopharyngitis 5.5% (placebo 4.9%) urinary tract infection 4.1% (placebo 6.7%) hyperglycaemia 2.3% (placebo 12.4%) NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 25mg hypoglycaemia 12.9% (placebo 9.8%) urinary tract infection 6.9% (placebo 6.7%) nasopharyngitis 6% (placebo 4.9%) NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 25mg hypoglycaemia 8.9% (placebo 9.8%) hyperglycaemia 7.9% (placebo 12.4%) nasopharyngitis 5% (placebo 4.9%) NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 25mg nasopharyngitis 7% (placebo 4.9%) upper respiratory tract infections 4.2% (placebo 5.3%) urinary tract infection 4.2% (placebo 6.7%) NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 25mg nasopharyngitis 7.2% (placebo 4.9%) urinary tract infection 7.2% (placebo 6.7%) diarrhoea 5.8% (placebo 0%) NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 10 mg headache 16.2% (placebo 15.5%) hypoglycaemia 16.2% (placebo 12.1%) vitamin d deficiency 13.5% (placebo 13.8%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 25 mg hypoglycaemia 17.2% (placebo 12.1%) blood ketone body increased 10.3% (placebo 3.4%) headache 10.3% (placebo 15.5%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 10 mg constipation 10.8% (placebo 4.7%) pyrexia 6.2% (placebo 4.7%) nasopharyngitis 4.6% (placebo 6.3%) NCT04531462 · Phase 4 · registry result, not featured evidence 10 mg nasopharyngitis 34.9% (placebo 31.1%) hypoglycaemia 27.9% (placebo 21.1%) pollakiuria 10.5% (placebo 2.2%) NCT02589639 · Phase 4 · registry result, not featured evidence 25 mg hypoglycaemia 27.8% (placebo 21.1%) nasopharyngitis 26.7% (placebo 31.1%) pollakiuria 10% (placebo 2.2%) NCT02589639 · Phase 4 · registry result, not featured evidence 10 mg viral upper respiratory tract infection 31.3% fall 3.1% influenza 0% NCT02589626 · Phase 4 · registry result, not featured evidence 25mg viral upper respiratory tract infection 33.3% influenza 9.1% fall 6.1% NCT02589626 · Phase 4 · registry result, not featured evidence 10 mg hypoglycaemia 20.5% (placebo 15.1%) urinary tract infection 8.2% (placebo 13.7%) hyperlipidaemia 5.5% (placebo 2.7%) NCT04233801 · Phase 3 · registry result, not featured evidence 25 mg hypoglycaemia 15.1% (placebo 15.1%) urinary tract infection 8.2% (placebo 13.7%) hyperlipidaemia 5.5% (placebo 2.7%) NCT04233801 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg viral upper respiratory tract infection 26.7% (placebo 22.2%) blood ketone body increased 13.8% (placebo 10.2%) back pain 6% (placebo 2.8%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg viral upper respiratory tract infection 15% (placebo 22.2%) back pain 2.8% (placebo 2.8%) contusion 2.8% (placebo 0.9%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg-25 mg lipase increased 7.5% (placebo 3.9%) cough 6.3% (placebo 1.3%) upper respiratory tract infection 2.5% (placebo 5.2%) NCT02182830 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg nasopharyngitis 3.6% (placebo 7.3%) lipase increased 2.7% (placebo 5.5%) urinary tract infection 2.7% (placebo 6.4%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg urinary tract infection 7.1% (placebo 6.4%) nasopharyngitis 4.5% (placebo 7.3%) lipase increased 3.6% (placebo 5.5%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg qd dyslipidaemia 8.7% urinary tract infection 7% upper respiratory tract infection 2.9% NCT01719003 · Phase 3 · registry result, not featured evidence 25 mg qd urinary tract infection 7.8% dyslipidaemia 6.6% upper respiratory tract infection 4.2% NCT01719003 · Phase 3 · registry result, not featured evidence 12.5 mg Bid + 1000 mg Bid diarrhoea 7.5% dizziness 5.7% gastritis 5.7% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 12.5 mg Bid + 1000 mg Bid urinary tract infection 10.6% diarrhoea 7.1% dyslipidaemia 4.7% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 12.5 mg Bid + 500 mg Bid urinary tract infection 10% dizziness 5.3% diarrhoea 3.5% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 5 mg Bid + 1000 mg Bid urinary tract infection 7% dyslipidaemia 4.7% upper respiratory tract infection 4.7% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 5 mg Bid + 500 mg Bid dyslipidaemia 8.9% diarrhoea 5.3% urinary tract infection 5.3% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 10 mg nasopharyngitis 10% (placebo 4.8%) anal inflammation 0% (placebo 0%) bartholinitis 0% (placebo 0%) NCT01947855 · Phase 3 · registry result, not featured evidence 25 mg anal inflammation 5.3% (placebo 0%) bartholinitis 5.3% (placebo 0%) pollakiuria 5.3% (placebo 0%) NCT01947855 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.1% glomerular filtration rate decreased 3.8% hyperkalaemia 3.8% NCT05254002 · Phase 2 · registry result, not featured evidence hyperkalaemia 9.3% glomerular filtration rate decreased 6.3% diarrhoea 3.4% NCT05254002 · Phase 2 · registry result, not featured evidence · combination 25 mg ketosis 19.4% (placebo 3.3%) fatigue 9.7% (placebo 0%) headache 9.7% (placebo 10%) NCT02632747 · Phase 2 · registry result, not featured evidence 10 mg QD urinary tract infection 6.8% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence 25 mg QD urinary tract infection 4.6% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence 12.5 mg BID urinary tract infection 4.6% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence 5 mg BID urinary tract infection 3.7% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence | — |
Notes
- aPopulation comparability has not been reviewed for 31 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Empagliflozin
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 18 more results
show 5 more results
show 3 more results
+ 24 further endpoints in the CSV export.
Chronic Kidney Disease
Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline
Empagliflozin · Jardiance
Marketed by Boehringer Ingelheim and partners
NCT03594110 · Phase 3 · completed
Patients with chronic kidney disease (6,609) were randomly assigned to empagliflozin 10 mg or matching placebo under double-blind conditions. The primary outcome was a composite of kidney disease progression or cardiovascular death. It was registered for the active trial and again for the whole study, which added up to 2 years of follow-up after the study drug stopped. Empagliflozin reduced the outcome in the active trial (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001) and over the whole study (hazard ratio 0.79, 95% CI 0.72 to 0.87). The figures come from the two published papers (N Engl J Med 2023 and 2025).
Next expected readout: December 2026 · NCT05786443 (registry estimate)
Reported efficacy
Time to first kidney disease progression or cardiovascular death (adjudicated): in the interventional part (up to 1136 days) and over the overall study including post-trial follow-up (up to 1869 days): Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met. (met)
Result source: NCT03594110
Enavogliflozin · Envlo
Marketed by Daewoong Pharmaceutical and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Empagliflozin | Enavogliflozin |
|---|---|---|
| Kidney composite outcome | 6.1% vs 8.1%−2 vs placeboNCT035941101 other result
| —Trial running · NCT06606093 |
| UACR, % change | -39.1% vs -2.6%−36.5 vs placeboNCT051828405 other results
| —Trial running · NCT06606093 |
| eGFR slope | —Not posted · NCT05373680 | —Trial running · NCT06606093 |
| Haemoglobin, change | —Not posted · NCT05373680 | —Trial running · NCT06606093 |
Kidney composite outcome
- Empagliflozin
- 6.1% vs 8.1%−2 vs placeboNCT03594110
1 other result
- 7.5% vs 8.9% NCT03594110
- Enavogliflozin
- —Trial running · NCT06606093
UACR, % change
- Empagliflozin
- -39.1% vs -2.6%−36.5 vs placeboNCT05182840
5 other results
- -36.6% vs -2.6% NCT05182840
- -22.4% vs -2.6% NCT05182840
- -19% vs -10.6% NCT05182840
- -45.9% vs -10.6% NCT05182840
- -40.3% vs -10.6% NCT05182840
- Enavogliflozin
- —Trial running · NCT06606093
eGFR slope
- Empagliflozin
- —Not posted · NCT05373680
- Enavogliflozin
- —Trial running · NCT06606093
Haemoglobin, change
- Empagliflozin
- —Not posted · NCT05373680
- Enavogliflozin
- —Trial running · NCT06606093
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Enavogliflozin: no structured comparison results are available for Chronic Kidney Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Empagliflozin: 4 of 4 rows · Enavogliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Empagliflozin |
|---|---|
| Dropout rate | 22.9%10 mga NCT03594110 · Phase 3 show 9 more results—Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 12.1%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —10 mg NCT05182840 · Phase 2 · registry result, not featured evidence —20 mg NCT05182840 · Phase 2 · registry result, not featured evidence —10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 7.2%10 mga NCT03594110 · Phase 3 show 9 more results—Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 4.8%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —10 mg NCT05182840 · Phase 2 · registry result, not featured evidence —20 mg NCT05182840 · Phase 2 · registry result, not featured evidence —10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 33%10 mga NCT03594110 · Phase 3 show 9 more results6.4%Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence 7.1%Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination —Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence 5.6%10 mg NCT05182840 · Phase 2 · registry result, not featured evidence 8.3%20 mg NCT05182840 · Phase 2 · registry result, not featured evidence 9.6%10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination 6.8%10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination 5.3%10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination 4.3%3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 8 more resultsnasopharyngitis 4.1% glomerular filtration rate decreased 3.8% hyperkalaemia 3.8% NCT05254002 · Phase 2 · registry result, not featured evidence hyperkalaemia 9.3% glomerular filtration rate decreased 6.3% diarrhoea 3.4% NCT05254002 · Phase 2 · registry result, not featured evidence · combination 10 mg glomerular filtration rate decreased 9.9% (placebo 4.1%) hyperkalaemia 9.9% (placebo 5.5%) cortisol decreased 5.6% (placebo 0%) NCT05182840 · Phase 2 · registry result, not featured evidence 20 mg hyperkalaemia 23.6% (placebo 5.5%) glomerular filtration rate decreased 8.3% (placebo 4.1%) upper respiratory tract infection 4.2% (placebo 2.7%) NCT05182840 · Phase 2 · registry result, not featured evidence 10 mg + 10 mg hyperkalaemia 15.1% (placebo 5.5%) glomerular filtration rate decreased 11% (placebo 4.1%) hypotension 5.5% (placebo 0%) NCT05182840 · Phase 2 · registry result, not featured evidence · combination 10 mg + 20 mg glomerular filtration rate decreased 9.5% (placebo 4.1%) hyperkalaemia 9.5% (placebo 5.5%) upper respiratory tract infection 5.4% (placebo 2.7%) NCT05182840 · Phase 2 · registry result, not featured evidence · combination 10 mg + 3 mg hyperkalaemia 6.6% (placebo 5.5%) glomerular filtration rate decreased 5.3% (placebo 4.1%) cortisol decreased 2.6% (placebo 0%) NCT05182840 · Phase 2 · registry result, not featured evidence · combination 3 mg hyperkalaemia 11.4% (placebo 5.5%) cortisol decreased 4.3% (placebo 0%) upper respiratory tract infection 2.9% (placebo 2.7%) NCT05182840 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Empagliflozin
show 1 more result
show 1 more result
show 2 more results
show 5 more results
show 5 more results
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Empagliflozin's landscape · Enavogliflozin's landscape